Portfolio company Supira Medical announced FDA approval for its SUPPORT II pivotal trial and appointed D. Keith Grossman to its board of directors.
Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for high-risk patients undergoing interventional procedures or experiencing cardiogenic shock
Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for high-risk patients undergoing interventional procedures or experiencing cardiogenic shock.